Reservoir Health helps organizations shape the policy, narrative, and market environments to enable health care innovation to reach patients.
We integrate policy, market enablement, and communications to shape how health care innovations are understood, valued, accessed, and adopted. We work with organizations developing new therapies, devices, diagnostics, digital health solutions, and models of care.

Bringing Patient Experience into Formulary Decisions
Meaningful patient representation takes more than a seat at the table. Committees deciding which medicines health plans cover need both supported patient participation and routine consideration of evidence about patients’ experiences.
Reservoir’s Elisabeth Oehrlein and Joe Vandigo coauthored a Health Affairs Forefront article with Marc Boutin of the Innovation and Value Initiative, Stephen Taylor of the Arthritis Foundation, and Kimberly Westrich of the National Pharmaceutical Council. The authors examine what meaningful patient representation requires.
Why it matters:
Patients bring real-life insights into treatment burden, affordability and coverage barriers that clinical and economic data may not capture. Meaningful representation requires both support for patients to contribute and routine consideration of patient experience evidence. Together, these can help committees make coverage decisions that better reflect what matters to patients and families.
The context:
Health plans subject to the essential health benefits prescription drug requirements must include at least one patient representative on their pharmacy and therapeutics (P&T) committees as of January 1, 2026.
Zoom in:
The authors of the Health Affairs Forefront article identify four priorities for implementation:
The key distinction:
Patient representatives bring lived experience and judgment to committee discussions. Research with patients and caregivers can show where experiences differ and which concerns extend across a community. Representatives can help interpret that evidence and identify perspectives that are missing. Committees need both to understand how coverage decisions affect patients and families.
Bottom Line:
Success depends on whether patients’ perspectives influence the discussion and the decisions that follow.
That requires attention to both how patients participate and how patient experience evidence is considered.
Go deeper:
For more information, contact Elisabeth Oehrlein.

Preparing for Post-Midterm Congressional Oversight: Practical Steps Companies Can Take Now to Protect Corporate Reputation
With Democrats taking control of the House and Senate come January, party leaders have already signaled plans for expanded congressional oversight, and Democrats are expected to use every oversight tool at their disposal. Republicans may use the bully pulpit of social media and appearances in traditional media to counter Democrats’ investigations. This could create a far-reaching oversight environment that can leave companies caught in the middle as both parties make competing demands.
Companies should be prepared for the powerful investigative tools – from oversight letters and reports to subpoenas and high-profile hearings – that Congress can wield. Because these investigations often play out in public, companies under scrutiny can face significant reputational challenges and risks. Organizations that invest now in preparing for increased oversight activity will be best positioned to navigate potential reputational impact.
Our experience spans all sides of congressional investigations, including participating in committee preparation and planning; managing national media response around hearings and investigations; and supporting industries, trade associations and companies involved in every phase of oversight. We know the key steps companies facing congressional scrutiny can take now to respond effectively and protect corporate reputation when the stakes are highest.
The most effective responses to congressional oversight begin long before the committee letter arrives or an executive is called to testify. The companies that prepare in advance will be best positioned to manage the reputational impact that can accompany congressional scrutiny.
Reservoir Health is uniquely suited to help your organization manage the response to congressional investigations and navigate reputational challenges. Our multidisciplinary team brings decades of experience managing high-profile moments, with colleagues having served in key staff roles on congressional committees, in the media and at federal agencies and trade associations. We know how investigations unfold, what drives committee priorities and how the media shapes the story, and we pair that insight with deep policy expertise to help you anticipate tough questions, avoid missteps and respond with confidence. Backed by our proprietary PRISM research model, we can offer a clearer picture of how oversight affects your stakeholders and how to respond effectively.
Learn more here today.

Health Care AI’s Rules Are in Flux. The Burden of Proof Isn’t.
While Washington is weighing how to regulate health care AI, the companies bringing these new technologies to market face a tougher test: proving they work, deliver clinical value and cost savings, and can close a trust gap with patients, clinicians and health systems.
Two recent developments underscore that tension. The Department of Health and Human Services (HHS) finalized a rule that eliminates certain AI transparency requirements, while outgoing Senate HELP Committee Chair Bill Cassidy unveiled a draft framework for how health care AI is paid for and regulated.
The midterm election results add another new variable. With Democrats taking control of Congress in January, health care AI is likely to face new questions and more oversight from Capitol Hill even as the administration weighs its options. But divided government rarely produces new laws quickly, so federal rules may stay unsettled for some time. Companies must earn trust now, with fewer federal standards to lean on and more scrutiny of how they do it.
Transparency Is Now a Market Differentiator
HHS’s new rule removes required disclosures on how certain AI decision-support tools in certified health IT systems, such as electronic health records, are developed, evaluated and used. What was a compliance requirement is now a competitive opening.
Hospitals, physicians, and several medical societies pushed to keep the disclosures, warning that without them, the work of vetting AI tools would fall on providers. Regulators countered that the disclosures hadn’t measurably improved patient care.
Both may be right. Health systems still need to know what they’re buying and the prior disclosures provided little clarity. The same is true across the market: payers want proof of value; employers want evidence before offering AI tools to their workforce; and consumers want to know how AI uses their data. Companies that provide each audience evidence it can act on will stand out.
What Health Care AI Will Have to Prove Next
Cassidy’s draft, the PATIENT AI Act, may never become law, but it raises three questions every health care AI company will face, whoever writes the rules.
1. Who is accountable when AI gets it wrong? The draft would clarify which agency oversees each type of AI tool, reaffirm existing federal limits on some state lawsuits against software-based medical devices, but leave the broader question of liability to further study. For consumer-facing tools that aren’t regulated as devices, the answer is even less settled. Companies that define their own accountability now will be better positioned when Washington does.
2. What evidence earns trust? As federal disclosure rules recede, accreditors and states are stepping in with standards of their own. The Joint Commission, the nation’s leading hospital accreditor, now offers voluntary certification for health systems that govern and monitor the AI they deploy. States are writing rules for consumer-facing AI, from chatbot disclosures to limits on AI in mental health care. Each sets expectations that companies will have to meet.
3. How will reimbursement for AI evolve? The draft would set up a process for Medicare to decide whether and how to pay for AI services, including a pilot to test paying for AI that performs certain clinical tasks on its own. The business question is clear: what evidence of benefit, safety and value will justify reimbursement?
What Companies Should Do Now
Whether you’re a technology platform, consumer health company, clinical workflow vendor or diagnostics developer, three priorities stand out:
The Bottom Line
The rules for health care AI are still being written, and a divided Washington may pull them in different directions. The market’s questions are more settled: Does it work? Where does it fit? Can it be trusted? Companies with credible answers will be ready for whatever comes next.
At Reservoir Health, we help companies bringing AI into health care understand the policy forces shaping their markets, identify stakeholder concerns and develop positioning and communications that explain their value and earn trust.